Compound breakdown

The four peptides in Clavicular's stack

Four research peptides come up repeatedly in discussion of Clavicular's protocol — Retatrutide, BPC-157, TB-500, and CJC-1295 No DAC. This page is a compound-by-compound breakdown of what each one is, which catalogue category it sits in, and how the four cluster across very different mechanisms. It is not a bundle, not a recommended sequence, and not a dosing guide. Each compound is sold as its own SKU and reaches a researcher one vial at a time; the grouping here is descriptive — a way of looking at the four together because that is how they are most often discussed — not a prescriptive protocol. The body of the page explains why these specific four are grouped, what each one does at the receptor level, and how the price ladder falls when you stack them on a single order page.

For laboratory research use only. Not for human consumption. Clav Tides is not affiliated with Clavicular (Braden Peters) — the page collects publicly referenced compounds and is for technical review only.

Why these four

Three different mechanisms, one common discussion

The four compounds on this page do not belong to a single catalogue category. They are spread across three. Retatrutide sits under GLP / Weight Loss because its mechanism is metabolic — triple-agonist action on GLP-1, GIP, and glucagon receptors. BPC-157 and TB-500 both sit under Recovery & Healing because both are tissue-repair peptides that show up together in published research on muscle, tendon, and gut barrier work. CJC-1295 No DAC sits under Growth Hormone because its mechanism — GHRH receptor activation — affects pituitary growth-hormone release rather than fat metabolism or tissue repair directly.

That spread is the point. The four cover three different reasons a researcher comes to the catalogue without overlapping each other, which is why they are clustered in public discussion. A researcher ordering all four is not paying twice for the same effect class; a researcher ordering only two is making a choice about which mechanism to prioritise first. None of that constitutes a recommended sequence or a recommended dose; it is simply how the four compounds' catalogue positions cluster.

One at a time

What each compound is

01 · Metabolic compound

Retatrutide 15mg

Triple GLP-1 / GIP / glucagon receptor agonist

Catalogue category: GLP / Weight Loss

Retatrutide is the metabolic line in this group and the reason the four are usually discussed together. It acts on three receptors — GLP-1, GIP, and glucagon — rather than the single GLP-1 target older agonists rely on, which is why it sits in the GLP / Weight Loss catalogue category by itself rather than alongside the recovery peptides. The 15 mg vial is the smallest of the three published sizes on the supplier's listing; the heavier sizes (20 mg, 30 mg) cost less per milligram and tend to be what researchers move to after the entry vial. Because the line carries the largest share of the total cost across the four, it is the one most people order separately first if they're working to a budget.

Per-vial catalogue price: $179.99. Full listing →

02 · Recovery compound

BPC-157 10mg

15-amino-acid pentadecapeptide (Body Protection Compound-157)

Catalogue category: Recovery & Healing

BPC-157 is a synthetic 15-amino-acid sequence derived from a gastric protein. It sits in the Recovery & Healing catalogue category and is almost always grouped with TB-500 — the two share a category, share a price band, and share a research literature for tissue repair. At under $55 per 10 mg vial it is the lowest-cost line in the four, which is why it is usually the first vial researchers add to a small recovery-focused order. The compound is short enough to be relatively cheap to synthesise, which keeps the catalogue price down even as supply tightens elsewhere.

Per-vial catalogue price: $53.99. Full listing →

03 · Recovery compound

TB-500 (Thymosin Beta-4) 10mg

Thymosin Beta-4 fragment (Ac-LKKTETQ active region)

Catalogue category: Recovery & Healing

TB-500 is a synthetic fragment built around the active region of Thymosin Beta-4. It shares the Recovery & Healing category with BPC-157 and is priced identically, so the two read as a matched pair on the order page rather than two separate purchase decisions. Buyers who want the recovery side of the protocol without taking on the metabolic or growth-hormone lines usually buy these two and stop there, which makes the recovery pair the most common partial order across the four compounds.

Per-vial catalogue price: $53.99. Full listing →

04 · Growth-hormone-axis compound

CJC-1295 No DAC 10mg

GHRH analog, no Drug Affinity Complex (short half-life variant)

Catalogue category: Growth Hormone

CJC-1295 No DAC is a growth-hormone-releasing-hormone (GHRH) analog. The "No DAC" designation marks the variant without the Drug Affinity Complex modification — a distinct SKU from the DAC version, with a shorter half-life and a different research dosing pattern. It sits in the Growth Hormone catalogue category by itself in this set and is the mid-priced line of the four, between the cheap recovery pair and Retatrutide. If you specifically need the DAC variant, confirm it on the listing before ordering, because this page references the No DAC line.

Per-vial catalogue price: $71.99. Full listing →

Reference

Per-vial catalogue prices, side by side

The figures below are catalogue prices pulled from this site's product data. They are per vial, not per dose or per cycle. Retatrutide carries the largest share of the total on its own; the two recovery peptides are priced identically.

CompoundPer vial
Retatrutide 15mg

Metabolic compound

$179.99
BPC-157 10mg

Recovery compound

$53.99
TB-500 (Thymosin Beta-4) 10mg

Recovery compound

$53.99
CJC-1295 No DAC 10mg

Growth-hormone-axis compound

$71.99
Total if all four ordered together$359.96

Related reading

Continue with

Compare three protocols

Budget, Clavicular, and Ultimate — side-by-side comparison with mechanism and cost breakdowns.

Read the comparison

What peptides does Clavicular use

The longer-form companion piece — what is publicly referenced versus what is inferred from his stack discussion.

Read the breakdown